Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.

To claim your copy free of charge simply follow this link.

Stanley Erck Biography and Net Worth

CEO of Novavax

Mr. Erck was named president and chief executive officer of Novavax in April 2011. He became a Novavax director in June 2009 and served as its executive chairman of the board beginning in February 2010. From 2000 to 2008, Mr. Erck was president and chief executive officer of IOMAI Corporation, leading the company through an initial public offering and a merger with Intercell, an Austrian vaccine company, and through the development of a late-stage infectious disease product candidate. Mr. Erck previously served as president and chief executive officer at Procept, a publicly traded immunology company, as vice president of corporate development at Integrated Genetics (now Genzyme), and in management positions within Baxter International. Mr. Erck currently sits on the board of directors of MaxCyte, Inc. He received an undergraduate degree from the University of Illinois and a master’s degree in business administration from the University of Chicago Booth School of Business.

What is Stanley C. Erck's net worth?: The estimated net worth of Stanley C. Erck is at least $2.19 million as of October 2nd, 2024. Mr. Erck owns 269,118 shares of Novavax stock worth more than $2,190,621 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Erck may own. Learn More about Stanley C. Erck's net worth.
How do I contact Stanley C. Erck?: The corporate mailing address for Mr. Erck and other Novavax executives is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. Novavax can also be reached via phone at (240) 268-2000 and via email at [email protected]. Learn More on Stanley C. Erck's contact information.
Has Stanley C. Erck been buying or selling shares of Novavax?: Stanley C. Erck has not been actively trading shares of Novavax during the last quarter. Most recently, Stanley C. Erck sold 42,829 shares of the business's stock in a transaction on Monday, October 4th. The shares were sold at an average price of $176.15, for a transaction totalling $7,544,328.35. Learn More on Stanley C. Erck's trading history.
Who are Novavax's active insiders?: Novavax's insider roster includes Stanley Erck (CEO), Gary Evans (Director), Gregory Glenn (Insider), John Herrmann, II (President, CEO & Director), Rachel King (Director), Michael McManus, Jr. (Director), David Mott (Director), John Trizzino (CFO), and James Young (Director). Learn More on Novavax's active insiders.
Are insiders buying or selling shares of Novavax?: During the last twelve months, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 62,312 shares worth more than $866,211.80. The most recent insider tranaction occured on June, 21st when Director James F Young sold 7,500 shares worth more than $105,675.00. Insiders at Novavax own 1.0% of the company. Learn More about insider trades at Novavax.
Information on this page was last updated on 6/21/2024.

Stanley C. Erck Insider Trading History at Novavax

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/4/2021	Sell	42,829	$176.15	$7,544,328.35
10/1/2021	Sell	49,000	$175.10	$8,579,900.00
7/2/2021	Sell	52,559	$215.89	$11,346,962.51	35,676
10/1/2020	Sell	2	$108.57	$217.14	32,210
9/29/2020	Sell	4,112	$107.80	$443,273.60	49,606
5/14/2018	Buy	100,000	$1.65	$165,000.00	328,279
11/9/2017	Buy	100,000	$1.13	$113,000.00	228,279
5/11/2017	Buy	50,000	$0.84	$42,000.00	128,279
3/31/2016	Sell	424,778	$5.19	$2,204,597.82	301,066
1/31/2016	Buy	2,072	$4.38	$9,075.36
1/31/2015	Buy	6,122	$2.28	$13,958.16
7/31/2014	Buy	6,788	$2.28	$15,476.64

Stanley C. Erck Buying and Selling Activity at Novavax

Novavax Company Overview

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Today's Range

Now: $8.14

$7.96

$8.18

50 Day Range

MA: $10.99

$7.22

$14.68

2 Week Range

Now: $8.14

$3.53

$23.86

Volume

723,203 shs

Average Volume

9,690,543 shs

Market Capitalization

$1.30 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.1

Download Our Tesla Ebook For Free

From DTI | Ad